The Food and Drug Administration cautioned that DPP‐4 suppressors may increase the risk of serious arthralgia,19 attracting great attention, revealing 33 serious arthralgia cases after using DPP‐4 inhibitors over a 7‐year period, but no case developed arthralgia in the yogliptin treatment groups in this research. Here, DPP4 is linked to Arthralgia.